Leonor Laredo

Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Francisco J. de Abajo, Sara Rodríguez‐Martín, Victoria Lerma et al. · The Lancet · 2020 · 422 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +7

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 175 citations · Full text

Veterinary Medicine, Infectious Diseases, Molecular Virology +16

Risk of Cerebrovascular Accident Associated with Use of Antipsychotics: Population‐Based Case–Control Study

Leonor Laredo, Emilio Vargas, Antonio Javier Blasco et al. · Journal of the American Geriatrics Society · 2011 · 38 citations

Medicine, Geriatric Medicine, Psychiatry +15

Lack of Pharmacokinetic Interaction Between Omeprazole or Lansoprazole and Ivabradine in Healthy Volunteers: An Open‐Label, Randomized, Crossover, Pharmacokinetic Interaction Clinical Trial

Antonio Portolés, Aitana Calvo, Ana Terleira et al. · The Journal of Clinical Pharmacology · 2006 · 34 citations

Medicine, Pharmacokinetics, Pharmacology +14